Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.75 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.59 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | PLG | P00747 | 2/20 | 0.58 |
| ▸ | PLAT | P00750 | 2/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.58 |
| ▸ | PROC | P04070 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melagatran SCHEMBL27652 | 0.86 | F2 (0.64) | F2F10PROC | |
| Melagatran SCHEMBL8083301 | 0.86 | F2 (0.64) | F2F10PROC | |
| Melagatran SCHEMBL20567754 | 0.86 | F2 (0.64) | F2F10PROC | |
| Melagatran SCHEMBL23840802 | 0.86 | F2 (0.64) | F2F10PROC | |
| SCHEMBL23794105 | 0.86 | F2 (0.58) | F2F10PLGPROC | |
| SCHEMBL23793672 | 0.85 | F2 (0.61) | F2 | |
| Melagatran SCHEMBL3209070 | 0.85 | F2 (0.63) | F2F10PROC | |
| Melagatran SCHEMBL5706395 | 0.85 | F2 (0.63) | F2F10PROC | |
| Melagatran SCHEMBL29160734 | 0.85 | F2 (0.63) | F2F10PROC | |
| Melagatran SCHEMBL27557537 | 0.85 | F2 (0.63) | F2F10PROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F2 4188/4885PRSS1 148/4885F10 4171/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4188/4885PRSS1 148/4885F10 4171/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | F2 36/4885PRSS1 244/4885F10 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.